Hyperion Therapeutics Inc., of Brisbane, Calif., said it amicably resolved its disputes, and entered a completion of phase III trial, option and mutual release agreement with Clal Biotechnology Industries Ltd. (CBI), of Ramat Gan, Israel, and Yeda Research and Development Co. Ltd. regarding Diapep277, a product candidate developed by Andromeda Biotech Ltd., a company which Hyperion acquired from CBI in June 2014.